|Lpath is the category leader in lipidomic-based therapeutics||Lpath's Founder helped pioneer the bioactive lipid signaling space, which is an important emerging area of drug discovery [see Nature Reviews (February 2008) and The British Journal of Cancer (October 2006)]. As such, we have deep and broad knowledge of lipids and how to work with them. Moreover, we have demonstrated a unique ability, using our ImmuneY2™ technology, to generate monoclonal antibodies against bioactive lipids, setting us apart from the rest of the field.|
|Powerful Pipeline Capability||We used our proprietary ImmuneY2 drug-discovery engine to develop the first ever monoclonal antibodies against bioactive lipids. The first was Sphingomab™, whose ocular formulation is called iSONEP™ and whose systemic formulation is called ASONEP™; the second was Lpathomab™. With this ImmuneY2 platform technology, we continue to generate novel antibodies against other bioactive-lipid targets, thus creating a compelling pipeline of therapeutic candidates.|
|Superior Intellectual Property||Lpath has over 50 issued or pending patents in the U.S. (with corresponding patent protection in Europe, Japan, etc.). Issued patent claims provide ownership of anti-sphingolipid therapeutic antibodies as compositions of matter; several patents issued and pending provide broad coverage of bioactive lipids as targets in the treatment of several diseases, including cancer, cardiovascular diseases, inflammation, autoimmune disorders, ocular disease and pathogenic angiogenesis. Because Lpath is a pioneer in the field, many of these issued and allowed patents may be considered dominating.|
|Experienced Executive & Advisory Team||Scott Pancoast, CEO: Harvard MBA, broad management/CEO experience; venture capitalist for 11 years with focus on biotech.
Gary Atkinson, CFO: over 25 years experience in corporate finance and accounting for public and private companies.
Dario Paggiarino, M.D., SVP & Chief Development Officer: over 25 years experience in large and small pharma developing product candidates in a number of clinical indications.
Gary Woodnutt, Ph.D., SVP, Research: over 25 years experience in drug discovery and pharmaceutical research with companies including GSK and Pfizer.
Roger Sabbadini, Ph.D., Founder: pioneer in bioactive lipid research; his lab has been studying the role of sphingolipid mediators in disease states for over 17 years.
Leigh Hsu, Ph.D., M.B.A., VP, Corporate Development: over 13 years experience in business development and transactional activity with pharma and research organizations.
Glenn Stoller, M.D., Head of Lpath Ocular: practicing retinal-eye surgeon; former advisor to Genentech and OSI/Eyetech.
We also utilize the services of several world-class consultants and advisory members with expertise in research, ophthalmology, CNS disease, oncology, inflammation, and diagnostics.